Citations

Showing 10 of 108162 citations.

Physician Workflow in Two Distinctive Emergency Departments: An Observational Study
Patel, Vimla L., Denton, Courtney A., Traub, Stephen J., Shapiro, Jason S. , Soni, Hiral , Kannampallil, Thomas

Mayo Clinic

Applied Clinical Informatics | March 4, 2021 | Volume: 12 | Issue: 01 | Pages: 141-152

10.1055/s-0040-1722615 | PMID 33657633 Get It

Abstract Objectives We characterize physician workflow in two distinctive emergency departments (ED). Physician practices mediated by electronic health records (EHR) are explored within the context of organizational complexity for the delivery of care. Methods Two urban clinical sites, including an academic teaching ED, were selected. Fourteen physicians were recruited. Overall, 62 hours of direct clinical observations were conducted characterizing clinical activities (EHR use, team communication, and patient care). Data were analyzed using qualitative open-coding techniques and descriptive statistics. Timeline belts were used to represent temporal events. Results At site 1, physicians, engaged in more team communication, followed by direct patient care. Although physicians spent 61% of their clinical time at workstations, only 25% was spent on the EHR, primarily for clinical documentation and review. Site 2 physicians engaged primarily in direct patient care spending 52% of their time at a workstation, and 31% dedicated to EHRs, focused on chart review. At site 1, physicians showed nonlinear complex workflow patterns with a greater frequency of multitasking and interruptions, resulting in workflow fragmentation. In comparison, at site 2, a less complex environment with a unique patient assignment system, resulting in a more linear workflow pattern. Conclusion The nature of the clinical practice and EHR-mediated workflow reflects the ED work practices. Physicians in more complex organizations may be less efficient because of the fragmented workflow. However, these effects can be mitigated by effort distribution through team communication, which affords inherent safety checks.
Genetic Predictors of Chemotherapy-Induced Peripheral Neuropathy from Paclitaxel, Carboplatin and Oxaliplatin: NCCTG/Alliance N08C1, N08CA and N08CB Study
Adjei, Araba A., Lopez, Camden , Schaid, Daniel J. , Sloan, Jeff A. , Le‐Rademacher, Jennifer , Loprinzi, Charles L. , Olson, Janet E., Beutler, Andreas S. , Vachon, Celine M. , Ruddy, Kathryn J. , Lopez, Camden L , Le-Rademacher, Jennifer G , Norman, Aaron D. , Olson, Janet E. , Couch, Fergus J. , Vachon, Celine M.

Mayo Clinic

Cancers | March 3, 2021 | Volume: 13 | Issue: 5 | Pages: 1084

10.3390/cancers13051084 | PMID 33802509 Get It

Chemotherapy-induced peripheral neuropathy (CIPN) is a common and potentially permanent adverse effect of chemotherapeutic agents including taxanes such as paclitaxel and platinum-based compounds such as oxaliplatin and carboplatin. Previous studies have suggested that genetics may impact the risk of CIPN. We conducted genome-wide association studies (GWASs) for CIPN in two independent populations who had completed European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ)-CIPN20 assessments (a CIPN-specific 20-item questionnaire which includes three scales that evaluate sensory, autonomic, and motor symptoms). The study population N08Cx included 692 participants from three clinical trials (North Central Cancer Treatment Group (NCCTG) N08C1, N08CA, and N08CB) who had been treated with paclitaxel, paclitaxel plus carboplatin, or oxaliplatin. The primary endpoint for the GWAS was the change from pre-chemotherapy CIPN20 sensory score to the worse score over the following 18 weeks. Study population The Mayo Clinic Breast Disease Registry (MCBDR) consisted of 381 Mayo Clinic Breast Disease Registry enrollees who had been treated with taxane or platinum-based chemotherapy. The primary endpoint for the GWAS assessed was the earliest CIPN20 sensory score available after the completion of chemotherapy. In multivariate model analyses, chemotherapy regimen (p = 3.0 × 10−8) and genetic ancestry (p = 0.007) were significantly associated with CIPN in the N08Cx population. Only age (p = 0.0004) was significantly associated with CIPN in the MCBDR population. The SNP most associated with CIPN was rs56360211 near PDE6C (p =7.92 × 10−8) in N08Cx and rs113807868 near TMEM150C in the MCBDR (p = 1.27 × 10−8). Due to a lack of replication, we cannot conclude that we identified any genetic predictors of CIPN.
Correction for: Signatures of cell stress and altered bioenergetics in skin fibroblasts from patients with multiple sclerosis
Wilkins, Jordan, Gakh, Oleksandr , Kabiraj, Parijat, Lucchinetti, Claudia F. , Wilkins, Jordan M, McCarthy, Christina B, McCarthy, Christina B. , Tobin, W. Oliver , Howe, Charles L.

Mayo Clinic

Aging | March 3, 2021 | Volume: 13 | Issue: 5 | Pages: 7707-7707

10.18632/aging.202757 | PMID 33657013 Get It

Certolizumab Trough Levels and Antibodies in Crohn Disease: A Single-Center Experience
Ramos, Guilherme Piovezani , Al‐Bawardy, Badr , Neto, Manuel B. Braga , Bledsoe, Adam C. , Quinn, Kevin P. , Heron, Valérie , Johnson, Amanda M. , Chedid, Victor , Papadakis, Konstantinos A. , Pardi, Darrell S. , Kane, Sunanda V. , Tremaine, William J., Raffals, Laura E. , Bruining, David H. , Faubion, William A. , Harmsen, William S. , Loftus, Edward V. , Braga Neto, Manuel Bonfim, Johnson, Amanda , Chedid, Victor G , Pardi, Darrell, Kane, S , Raffals, Laura , Loftus, Edward V , Braga Neto, Manuel B , Ramos, Guilherme P , Willrich, Maria Alice V. , Coelho–Prabhu, Nayantara , Kisiel, John B.

Mayo Clinic

Crohn's & Colitis 360 | March 3, 2021 | Volume: 3 | Issue: 3 | Pages: No page available

10.1093/crocol/otab019 | PMID 36776673 Get It

Abstract Background Certolizumab pegol (CZP) has been successfully used for the treatment of Crohn disease (CD); however, real-world data regarding the utility of CZP trough levels (CTLs) are lacking. We aimed to correlate CTL with CD outcomes and to determine frequency of CZP antibodies. Methods Retrospective evaluation of all CD patients on maintenance CZP with CTL obtained between 2016 and 2019. Outcomes included: median CTL, presence of anti-CZP antibodies, biochemical response (BR), clinical response (CR), radiologic response (RR), radiologic healing (RH), and mucosal healing (MH). Results Seventy-seven CD patients were included. Median CTL was 18.9 µg/mL (interquartile range, 7.6–35.4). Twenty-three patients (27.3%) had positive antibody levels, with lower median CTL compared to patients with no antibodies (0.0 vs 29.8; P < 0.0001). Median CTL levels were higher in patients with vs without CR (30.4 vs 10.3 µg/mL; P = 0.0015) and RR (29.6 vs 5.8 µg/mL; P = 0.006). CZP dosing at least every 2 weeks was associated with higher odds of achieving MH (odds ratio, 3.2; 95% confidence interval, 1.03–9.97). CTL resulted in change in clinical management in 62.7% of cases and presence of CMZ antibodies was associated with an odds ratio of 5.83 (95% confidence interval, 1.57–21.73) of change in management. Receiver operating characteristic curve and quartile analysis suggested that CTL >19 µg/mL is associated with increased rates of CR and RR. Conclusions Higher CTL was significantly associated with CR and RR. The rate of CZP antibodies was 27.3%. Our data suggest maintenance CTL of ≥19 µg/mL should be achieved in order to optimize outcomes in clinical practice.
The Clinical Characteristics and Treatment Outcomes of Concomitant Eosinophilic Esophagitis and Inflammatory Bowel Disease
Urquhart, Siri A. , Quinn, Kevin P. , Loftus, Edward V. , Loftus, Edward V , Ravi, Karthik

Mayo Clinic

Crohn's & Colitis 360 | March 3, 2021 | Volume: 3 | Issue: 2 | Pages: No page available

10.1093/crocol/otab018 | PMID 36778939 Get It

Abstract Background The clinical characteristics and treatment outcomes in patients with eosinophilic esophagitis (EoE) and inflammatory bowel disease (IBD) have not been extensively investigated. Methods We determined treatment outcomes and frequencies of disease-related complications in patients with EoE and IBD. Results Among 69 patients who met inclusion criteria, 39 (56.5%) had a diagnosis of Crohn disease. Clinical and histologic response rates to proton pump inhibitors and topical steroids were 25.9% and 24.4%, respectively. Conclusions Lower than expected clinical and histologic response rates for EoE suggest the combination of EoE and IBD is a medically refractory phenotype with more difficult to treat EoE.
Sex differences in acute cardiovascular care: a review and needs assessment
Vallabhajosyula, Saraschandra , Verghese, Dhiran , Desai, Viral , Sundaragiri, Pranathi R., Miller, Virginia M. , Desai, Viral K , Vallabhajosyula, Saraschandra

Mayo Clinic

Cardiovascular Research | March 3, 2021 | Volume: 118 | Issue: 3 | Pages: 667-685

10.1093/cvr/cvab063 | PMID 33734314 Get It

AbstractDespite significant progress in the care of patients suffering from cardiovascular disease, there remains a persistent sex disparity in the diagnosis, management, and outcomes of these patients. These sex disparities are seen across the spectrum of cardiovascular care, but, are especially pronounced in acute cardiovascular care. The spectrum of acute cardiovascular care encompasses critically ill or tenuous patients with cardiovascular conditions that require urgent or emergent decision-making and interventions. In this narrative review, the disparities in the clinical course, management, and outcomes of six commonly encountered acute cardiovascular conditions, some with a known sex-predilection will be discussed within the basis of underlying sex differences in physiology, anatomy, and pharmacology with the goal of identifying areas where improvement in clinical approaches are needed.
Successful Pregnancy Outcome With Connective Tissue Disease–Associated Interstitial Lung Disease
Colbenson, Gretchen A., Rose, Carl H., Ernste, Floranne C., Ryu, Jay H., Ryu, Jay H. , Ryu, Jay H , Colbenson, Gretchen A., Rose, Carl H., Ernste, Floranne C., Ryu, Jay H.

Mayo Clinic

JCR: Journal of Clinical Rheumatology | March 3, 2021 | Volume: 28 | Issue: 1 | Pages: e305-e307

10.1097/rhu.0000000000001725 | PMID 33657592 Get It

The Role of Genetic Testing in the Evaluation of Dilated Cardiomyopathies
Agboola, Kolade M. , McGill, Trevon, Boilson, Barry A. , Pereira, Naveen L. , Jentzer, Jacob C. , Jentzer, Jacob C

Mayo Clinic

Case Reports in Cardiology | March 3, 2021 | Volume: 2021 | Issue: No issue available | Pages: 1-4

10.1155/2021/6641108 | PMID 33763259 Get It

We present an adolescent African American male admitted to the cardiac intensive care unit with cardiogenic shock and acute respiratory failure. Through an overview of his presentation, diagnostic workup, and treatment, we demonstrate the clinical utility of genetic testing in the evaluation of unexplained dilated cardiomyopathies.
Automatic and Reliable Quantification of Tonic Dopamine Concentrations In Vivo Using a Novel Probabilistic Inference Method
Kim, Jaekyung , Barath, Abhijeet S. , Rusheen, Aaron E. , Cabrera, Juan M. Rojas , Price, J. Blair , Shin, Hojin , Goyal, Abhinav , Jondal, Danielle E. , Lee, Kendall H. , Jang, Dong Pyo , Rojas Cabrera, Juan M, Yuen, Jason W, Rojas Cabrera, Juan M , Yuen, Jason , Blaha, Charles D. , Oh, Yoonbae

Mayo Clinic

ACS Omega | March 3, 2021 | Volume: 6 | Issue: 10 | Pages: 6607-6613

10.1021/acsomega.0c05217 | PMID 33748573 Get It

Reduced calf muscle pump function is a risk factor for venous thromboembolism: a population-based cohort study
Houghton, Damon E. , Ashrani, Aneel A. , Liedl, David , Mehta, Ramila A. , Hodge, David O. , Rooke, Thom W. , Wennberg, Paul W. , Houghton, Damon E , Wysokiński, Waldemar E. , McBane, Robert D.

Mayo Clinic

Blood | March 3, 2021 | Volume: 137 | Issue: 23 | Pages: 3284-3290

10.1182/blood.2020010231 | PMID 33657212 Get It

Abstract The calf muscle pump is a major determinate of venous return in the legs but has not been studied as a risk factor for venous thromboembolism (VTE). A population-based cohort study of Olmsted County, Minnesota residents was performed using calf pump function (CPF) measurements from venous plethysmography studies from 1998 to 2015. Patients with a history of VTE were excluded. Nursing validated VTE outcomes from the Rochester Epidemiology Project were identified after the index study date, and patients with reduced CPF (rCPF) were compared with patients with normal CPF. A total of 1532 patients with recorded CPF (28% air and 72% strain gauge plethysmography) were included; 591 (38.5%) had normal CPF, 353 (23.0%) had unilateral rCPF, and 588 (38.3%) had bilateral rCPF. Any VTE occurred in 87 patients (5.7%) after a median follow-up of 11.7 years (range, 0-22.0 years). Comparing patients with bilateral reduced to bilateral normal CPF, the unadjusted hazard ratio (HR) for incident VTE was 2.0 (95% confidence interval [CI], 1.2-3.4) and after adjusting for age, BMI, and Charlson Comorbidity Index, the HR was 1.68 (95% CI, 0.98-2.89). The adjusted HR for ipsilateral deep vein thrombosis was evaluated in 3064 legs comparing legs with reduced to normal CPF and was 1.71 (95% CI, 1.03-2.84). Mortality was significantly higher in both the bilateral (P < .001) and unilateral (P < .001) rCPF groups compared with normal CPF. Our results demonstrate that CPF is a risk factor for VTE in an otherwise low-risk ambulatory population and might be a useful component in risk stratification models.